Portfolio
Portfolio

Pieris Pharmaceuticals

Developing Anticalin® product candidates to help patients suffering from cancer, severe asthma, anemia and other medical conditions with a high unmet medical need.

Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company applying its proprietary Anticalin® technology to create differentiated drugs that can help patients suffering from cancer, severe asthma, anemia and other medical conditions with a high unmet medical need.

Pieris has become a publicly traded company on December 18, 2014 (NASDAQ:PIRS).

  • CEO Stephen S. Yoder, J.D.
  • Industry Biotech
  • History IPO

Subscribe